RecruitingNCT06541860

DAratumumab and REvlimid REfractory MM

Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience


Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Enrollment

100 participants

Start Date

Aug 21, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.


Eligibility

Min Age: 18 Years

Inclusion Criteria8

  • Phase I
  • Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
  • Patients aged ≥ 18 years
  • Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
  • Phase II
  • Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
  • Patients aged ≥ 18 years
  • Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Exclusion Criteria1

  • Patients not willing to consent to review of clinical data

Locations(1)

Irccs San Matteo Pavia

Pavia, PV, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06541860


Related Trials